来源：Gangtise投研
三生制药（01530.HK）2024年度业绩交流会：2024年，三生制药整体业绩表现强劲，营收达91.1亿元人民币，同比增长16.5%，归母净利润20.9亿元，同比增长34.9%。核心产品特比奥收入50.6亿元，同比增长20.4%，市场占有率达67%；蔓迪销售额为13.37亿元，同比增长18.9%，其泡沫剂型产品成功获批上市。研发成果显著，3款新药获批上市，4款新药进入上市申报阶段，靶向PD-1/VEGF的双特异性抗体707在非小细胞肺癌等适应症的二期临床中疗效潜力优于竞品。此外，公司达成4项BD合作，包括引进司美格鲁肽注射液减重适应症等。
责任编辑：王若云
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.